Axim Biotechnologies IncOTC Pink - Limited Information:AXIM
- LAST PRICE0.0026
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0022/ 3,545
- Ask / Lots0.0029/ 2,100
- Open / Previous Close--- / 0.0026
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AXIM |
|---|---|---|
| 09:33 ET | 150000 | 0.003 |
| 10:06 ET | 2000 | 0.00262 |
| 10:13 ET | 1000 | 0.003 |
| 11:05 ET | 200000 | 0.0026 |
| 11:07 ET | 819981 | 0.0026 |
| 11:30 ET | 10000 | 0.00268 |
| 11:32 ET | 5000 | 0.00296 |
| 11:56 ET | 10000 | 0.0029 |
| 11:57 ET | 5000 | 0.00262 |
| 12:33 ET | 10000 | 0.0029 |
| 01:02 ET | 10000 | 0.0022 |
| 01:04 ET | 17008 | 0.0022 |
| 02:05 ET | 4000 | 0.00255 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Axim Biotechnologies Inc | 770.0K | -0.2x | --- |
PaxMedica Inc | 761.5K | 0.0x | --- |
Point of Care Nano-Technology Inc | 726.9K | 0.0x | --- |
Nutra Pharma Corp | 759.7K | 0.2x | --- |
Bellerophon Therapeutics Inc | 672.8K | -0.1x | --- |
NovAccess Global Inc | 594.3K | -0.1x | --- |
Company Information
Axim Biotechnologies, Inc. is a vertically integrated research and development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. Its core competencies include development of rapid lateral flow immunoassays, reagents, and monoclonal antibody development for such assays. Its product categories include Eye Health, wherein the Company acquired two FDA cleared tests for dye eye disease and has internally developed a third assay; and SARS-CoV-2 neutralizing antibody tests. The Company is focused on developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including SARS-Cov-2, Lactoferrin, IgE, Lacritin, and MMP-9. Its platform capability can also be applied to rapid testing for vaccine candidates. Its platform can also be used to enable point-of-care detection for one or more cancers using a unique cancer biomarker, QSOX1-L.
Contact Information
- Headquarters
- 6191 Cornerstone Court, E, Suite 114SAN DIEGO, CA, United States 92121
- Phone
- 212-751-0001
- Fax
- 775-786-6755
Executives
- President, Director
- Catalina Valencia
- Chief Financial Officer, Company Secretary
- Robert Malasek
- Chief Operating Officer
- Kurt Phinney
- Chief Medical Officer
- Joseph Tauber
- Director
- Peter O'Rourke
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $770.0K |
|---|---|
Revenue (TTM) | $92.9K |
Shares Outstanding | 302.0M |
Axim Biotechnologies Inc does not pay a dividend. | |
Beta | 1.06 |
EPS | $-0.02 |
Book Value | $-0.03 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 8.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,579.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
